All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Final Appraisal Recommendation

Advice No: 1116 – May 2016

Dulaglutide (Trulicity®▼) 1.5 mg and 0.75 mg solution for injection

Submission by Eli Lilly & Company Ltd

Recommendation of AWMSG

Dulaglutide (Trulicity®▼) is recommended as an option for restricted use within NHS Wales.

Dulaglutide (Trulicity®▼) should be restricted for use in the following subpopulation/circumstances within its licensed indication for the treatment of type 2 diabetes in adults to improve glycaemic control:

After failure, intolerance or where there is a contraindication to, standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy.

In combination with other glucose-lowering medicinal products but not including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control, in line with current NICE guidance.

Dulaglutide (Trulicity®▼) is not recommended for use within NHS Wales outside of this subpopulation/these circumstances.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 866), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Eli Lilly & Company Ltd
Date of first issue	May 2016
Last reviewed	May 2019